A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).
Rheumatoid Arthritis (RA)|Psoriatic Arthritis (PsA)
Incidence Rates of Overall Malignancies, Up to 5 years|Incidence Rates of Melanoma, Up to 5 years|Incidence Rates of Non-melanoma Skin Cancer, Up to 5 years|Incidence Rates of Basal Cell Carcinoma, Up to 5 years|Incidence Rates of Squamous Cell Carcinoma, Up to 5 years
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).